Skip to content
Home/Companies/Biotech/Highlight Therapeutics
Highlight Therapeutics

Highlight Therapeutics

Biotech·Spain·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Highlight Therapeutics?

Highlight Therapeutics is currently owned by Columbus Venture Partners through Columbus Life Science Fund II (2019 vintage), since 2020.

Hand-verified · updated 2026-08-09

Columbus Venture Partners
Investor
Columbus Venture Partners
Columbus Life Science Fund II · 2019 · Life Sciences VC

Key facts

HQSpain
SectorBiotech
StatusActive
Websitewww.highlighttherapeutics.com

More from Columbus Life Science Fund II

Other portfolio companies in the same fund.

Minoryx Therapeutics
Minoryx Therapeutics
Active
BiotechSpain· 2022
NeRRe Therapeutics
Active
BiotechUnited Kingdom· 2021
RECOVID Solutions
Exited 2022
HealthTechSpain· 2020
to
Sanifit Therapeutics
Exited 2021
BiotechSpain· 2019
to
Viralgen Commercial
Viralgen Commercial
Exited 2021
BiotechSpain· 2019
to
Radioterapia de Protones
Exited 2024
HealthcareSpain· 2017
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Highlight Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Highlight Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue